Form 4: Capricor Therapeutics Director Granted Stock Options

Capricor Therapeutics director David B. Musket received a grant of 15,500 stock options with an exercise price of $24.81, vesting monthly over 2026.

Summary

• David B. Musket, a Director of Capricor Therapeutics, Inc. (CAPR), was granted 15,500 stock options.
• The options have an exercise price of $24.81 per share.
• The transaction date for this grant was January 5, 2026.
• The options will vest at a rate of 1/12th on the first day of each month, commencing February 1, 2026, and concluding on December 31, 2026.
• The expiration date for these stock options is January 5, 2036.
• This award is compensation for annual board service.
• The option includes an early exercise feature, allowing purchase of shares prior to vesting, with such shares becoming restricted and subject to repurchase by the Issuer if service terminates early.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's a routine compensation event, it signifies continued board engagement and aligns director interests with shareholders, which is generally viewed favorably. There are no negative operational or financial implications directly from this filing.

Positives

• The grant of stock options aligns the financial interests of Director David B. Musket with those of the shareholders, incentivizing long-term company performance.
• This compensation package is a standard practice for attracting and retaining qualified board members, reflecting ongoing commitment to corporate governance.

Negatives

• The future exercise of these options could lead to a minor dilutive effect on existing shareholders, although this is a common aspect of equity-based compensation.

Risks

• If the reporting person elects to take advantage of the early exercise feature and purchases shares prior to vesting, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's operational or financial performance, focusing solely on an insider's equity transaction.

Industry Context

The grant of stock options to a director is a common form of executive and board compensation within the biotechnology and pharmaceutical industries, aiming to align leadership incentives with long-term shareholder value creation. This practice is consistent with industry standards for attracting and retaining experienced board members.

Comparison to Industry Standards

• The grant of stock options as compensation for board service is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule, monthly over a year, is a typical approach to ensure continued service and commitment from board members.
• The exercise price being set at the market price on the grant date is also standard for incentive stock options.

Corporate Governance

Related Party Transactions

• The grant of 15,500 stock options to David B. Musket, a Director of Capricor Therapeutics, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making. However, future exercise of options could result in minor dilution.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Keywords

Capricor Therapeutics, CAPR, Stock Options, Director Compensation, Insider Transaction, Equity Grant, SEC Form 4, Biotechnology